Drug General Information (ID: DDIWVCSPOD)
Drug Name			Drotrecogin alfa		Drug Info		Temsirolimus		Drug Info
Drug Type		Protein/peptide				Small molecule
Therapeutic Class		Coagulation Modifiers				Antineoplastics/Mtor Inhibitors

Mechanism of Drotrecogin alfa-Temsirolimus Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Drotrecogin alfa				Temsirolimus
Mechanism		Risk of bleeding Anticoagulant effects				Risk of bleeding Antiplatelet/anticoagulant effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Drotrecogin alfa and Temsirolimus

Recommended Action
Management		Patients receiving anticoagulants should be informed of the increased risk of developing intracerebral bleeding while on temsirolimus.

References
1	Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.